Show simple item record

dc.contributor.authorKimutai, Ren
dc.contributor.authorMusa, AMen
dc.contributor.authorNjoroge, Sen
dc.contributor.authorOmollo, Ren
dc.contributor.authorAlves, Fen
dc.contributor.authorHailu, Aen
dc.contributor.authorKhalil, EAGen
dc.contributor.authorDiro, Een
dc.contributor.authorSoipei, Pen
dc.contributor.authorMusa, Ben
dc.contributor.authorSalman, Ken
dc.contributor.authorRitmeijer, Ken
dc.contributor.authorChappuis, Fen
dc.contributor.authorRashid, Jen
dc.contributor.authorMohammed, Ren
dc.contributor.authorJameneh, Aen
dc.contributor.authorMakonnen, Een
dc.contributor.authorOlobo, Jen
dc.contributor.authorOkello, Len
dc.contributor.authorSagaki, Pen
dc.contributor.authorStrub, Nen
dc.contributor.authorEllis, Sen
dc.contributor.authorAlvar, Jen
dc.contributor.authorBalasegaram, Men
dc.contributor.authorAlirol, Een
dc.contributor.authorWasunna, Men
dc.date.accessioned2017-02-17T13:02:45Z
dc.date.available2017-02-17T13:02:45Z
dc.date.issued2017-01-09
dc.date.submitted2017-01-18
dc.identifier.citationSafety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. 2017 Clin Drug Investigen
dc.identifier.issn1179-1918
dc.identifier.pmid28066878
dc.identifier.doi10.1007/s40261-016-0481-0
dc.identifier.urihttp://hdl.handle.net/10144/618786
dc.description.abstractIn 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.
dc.language.isoenen
dc.publisherSpringer Linken
dc.rightsArchived with thanks to Clinical Drug Investigationen
dc.titleSafety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programmeen
dc.identifier.journalClinical Drug Investigationen
dc.internal.reviewer-noteClin Drug Investig - Springer Linken
refterms.dateFOA2019-03-04T13:07:24Z
html.description.abstractIn 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.


Files in this item

Thumbnail
Name:
Kimutai R et al - 2016 - Safety ...
Size:
579.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record